Innova Captab Limited (INNOVACAP) fundamentals
Innova Captab Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as INNOVACAP (ISIN INE0DUT01020). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Innova Captab Limited does
Innova Captab Limited is an integrated pharmaceutical company. The Company is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It has a presence across the pharmaceuticals value chain, including research and development, manufacturing, drug distribution and marketing and exports. Its business includes Contract Development and Manufacturing (CDMO) Services and Products, Domestic Branded Generics, and International Branded Generics. Its CDMO business provides research, product development and manufacturing services. Its Branded Generics business consists of the development, manufacture and distribution of generic formulation products, which are marketed and distributed in India under its own brand names through online and offline channels. Its generic drug products are also available online through various e-commerce pharmacy sites. It has developed a diversified branded generics product portfolio including tablets, capsules, dry syrups, and others.
Valuation and market data
| Last close | ₹1165.00 |
|---|---|
| Market capitalisation | ₹6,666 crore |
| Enterprise value | ₹6,914 crore |
| P/E (TTM) | 47.30 |
| Price to book | 6.11 |
| Price to sales (TTM) | 2.27 |
| Book value per share | ₹190.65 |
| Dividend yield | 17.17% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Fri Dec 29 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹1,637 crore | ₹188 crore | ₹141 crore | 24.63 |
| Mar 2025 | ₹1,256 crore | ₹171 crore | ₹128 crore | 22.41 |
| Mar 2024 | ₹1,094 crore | ₹130 crore | ₹94 crore | 18.66 |
| Mar 2023 | ₹936 crore | ₹92 crore | ₹68 crore | 14.16 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 50.9% |
|---|---|
| Foreign institutions (FII) | 0.3% |
| Mutual funds | 9.2% |
| Other domestic institutions | 10.7% |
| Retail and others | 28.8% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.